652 related articles for article (PubMed ID: 14660050)
21. CD34, CD4, and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies.
Cao TM; Wong RM; Sheehan K; Laport GG; Stockerl-Goldstein KE; Johnston LJ; Shizuru JA; Negrin RS; Lowsky R
Exp Hematol; 2005 Mar; 33(3):279-85. PubMed ID: 15730851
[TBL] [Abstract][Full Text] [Related]
22. Economic analysis of a phase III study of G-CSF vs placebo following allogeneic blood stem cell transplantation.
Stinson TJ; Adams JR; Bishop MR; Kruse S; Tarantolo S; Bennet CL
Bone Marrow Transplant; 2000 Sep; 26(6):663-6. PubMed ID: 11041569
[TBL] [Abstract][Full Text] [Related]
23. In vivo induction of T-cell hyporesponsiveness and alteration of immunological cells of bone marrow grafts using granulocyte colony-stimulating factor.
Jun HX; Jun CY; Yu ZX
Haematologica; 2004 Dec; 89(12):1517-24. PubMed ID: 15590404
[TBL] [Abstract][Full Text] [Related]
24. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation.
Huang XJ; Liu DH; Liu KY; Xu LP; Chen H; Han W; Chen YH; Zhang XH; Lu DP
Biol Blood Marrow Transplant; 2009 Feb; 15(2):257-65. PubMed ID: 19167686
[TBL] [Abstract][Full Text] [Related]
25. Association of natural killer cells in allografts with transplant outcomes in patients receiving G-CSF-mobilized PBSC grafts and G-CSF-primed BM grafts from HLA-haploidentical donors.
Zhao XY; Chang YJ; Xu LP; Liu DH; Liu KY; Huang XJ
Bone Marrow Transplant; 2009 Dec; 44(11):721-8. PubMed ID: 19377516
[TBL] [Abstract][Full Text] [Related]
26. [A comparative study of unrelated donor bone marrow transplantation and peripheral blood stem cell transplantation for their therapeutic effects on leukemia].
Fan ZP; Yang K; Liu QF; Sun J; Xu D; Zhang Y; Wei YQ; Ye CX; Jiang QL; Meng FY
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Oct; 26(10):1494-7, 1512. PubMed ID: 17062361
[TBL] [Abstract][Full Text] [Related]
27. The helper T lymphocyte precursor (HTLp) frequency does not predict outcome after HLA-identical sibling donor G-CSF-mobilised peripheral blood stem cell transplantation.
Healey G; Schwarer AP
Bone Marrow Transplant; 2002 Sep; 30(6):341-6. PubMed ID: 12235517
[TBL] [Abstract][Full Text] [Related]
28. Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor.
Herrera C; García-Pérez MJ; Ramirez R; Martín C; Alvarez MA; Martinez F; Gómez P; García-Castellano JM; Torres A
Bone Marrow Transplant; 1997 Mar; 19(6):545-51. PubMed ID: 9085733
[TBL] [Abstract][Full Text] [Related]
29. Different immune reconstitution in multiple myeloma, chronic myeloid leukemia and acute myeloid leukemia patients after allogeneic transplantation of peripheral blood stem cells.
Rondelli D; Re F; Bandini G; Raspadori D; Arpinati M; Senese B; Stanzani M; Bonifazi F; Falcioni S; Chirumbolo G; Tura S
Bone Marrow Transplant; 2000 Dec; 26(12):1325-31. PubMed ID: 11223973
[TBL] [Abstract][Full Text] [Related]
30. Individually adjusted prophylactic donor lymphocyte infusions after CD34-selected allogeneic peripheral blood stem cell transplantation.
Ferrá C; Rodríguez-Luaces M; Gallardo D; Encuentra M; Martín-Henao GA; Peris J; Ancín I; Sarrá J; Berlanga JJ; García J; Grañena A
Bone Marrow Transplant; 2001 Nov; 28(10):963-8. PubMed ID: 11753552
[TBL] [Abstract][Full Text] [Related]
31. Immune reconstitution after autologous hematopoietic stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications.
Steingrimsdottir H; Gruber A; Björkholm M; Svensson A; Hansson M
Haematologica; 2000 Aug; 85(8):832-8. PubMed ID: 10942930
[TBL] [Abstract][Full Text] [Related]
32. [T-cell-depleted HLA non-identical bone marrow transplantation in the child: prevention of graft-versus-host reaction by administration of donor T lymphocytes alloreactive against the recipient].
Cavazzana-Calvo M; André-Schmutz I; Hacein-Bey S; Schindler J; Vitetta H; Dupuis S; Quartier P; Chedeville G; Vilmer E; Casanova JL; Buffet R; Caillat-Zucman S; Radford I; Le Deist F; Fischer A
J Soc Biol; 2001; 195(1):65-8. PubMed ID: 11530503
[TBL] [Abstract][Full Text] [Related]
33. One-year cyclosporine prophylaxis reduces the risk of developing extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation.
Mengarelli A; Iori AP; Romano A; Cerretti R; Cerilli L; De Propris MS; Fenu S; Moleti ML; De Felice L; Girelli G; Arcese W
Haematologica; 2003 Mar; 88(3):315-23. PubMed ID: 12651271
[TBL] [Abstract][Full Text] [Related]
34. A pilot study of allogeneic bone marrow transplantation using related donors stimulated with G-CSF.
Isola LM; Scigliano E; Skerrett D; Shank B; Ross V; Najfeld V; Fruchtman S
Bone Marrow Transplant; 1997 Dec; 20(12):1033-7. PubMed ID: 9466275
[TBL] [Abstract][Full Text] [Related]
35. Allogeneic peripheral blood stem cell transplantation with CD34+-cell selection and delayed T-cell add-back in adults. Results of a single center pilot study.
Martino R; Martín-Henao G; Sureda A; Altés A; Canals C; Brunet S; Sierra J
Haematologica; 2000 Nov; 85(11):1165-71. PubMed ID: 11064469
[TBL] [Abstract][Full Text] [Related]
36. Growth factors and DLI in adult haploidentical transplant: a three-step pilot study towards patient and disease status adjusted management.
Lewalle P; Delforge A; Aoun M; Crombez P; de Wilde V; Theunissen K; Lagneaux L; Nowak B; Misplon V; Bron D; Martiat P
Blood Cells Mol Dis; 2004; 33(3):256-60. PubMed ID: 15528140
[TBL] [Abstract][Full Text] [Related]
37. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning.
Ogawa H; Ikegame K; Yoshihara S; Kawakami M; Fujioka T; Masuda T; Taniguchi Y; Hasei H; Kaida K; Inoue T; Kim EH; Kawase I
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1073-84. PubMed ID: 17084371
[TBL] [Abstract][Full Text] [Related]
38. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Ringdén O; Labopin M; Gorin NC; Le Blanc K; Rocha V; Gluckman E; Reiffers J; Arcese W; Vossen JM; Jouet JP; Cordonnier C; Frassoni F
J Clin Oncol; 2004 Feb; 22(3):416-23. PubMed ID: 14691124
[TBL] [Abstract][Full Text] [Related]
39. A randomized double-blind trial of hydroxychloroquine for the prevention of chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation.
Fong T; Trinkaus K; Adkins D; Vij R; Devine SM; Tomasson M; Goodnough LT; Lopez S; Graubert T; Shenoy S; Dipersio JF; Khoury HJ
Biol Blood Marrow Transplant; 2007 Oct; 13(10):1201-6. PubMed ID: 17889357
[TBL] [Abstract][Full Text] [Related]
40. Reduced-intensity conditioning followed by allografting of CD34-selected stem cells and < or =10(6)/kg T cells may have an adverse effect on transplant-related mortality.
Hartwig UF; Winkelmann N; Wehler T; Kreiter S; Schneider PM; Meyer RG; Ullmann AJ; Huber C; Kolbe K; Herr W
Ann Hematol; 2005 May; 84(5):331-8. PubMed ID: 15726363
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
